TY - JOUR
T1 - Prevention and management of co-morbidities in SLE
AU - Bichile, Tanmayee
AU - Petri, Michelle
N1 - Funding Information:
Funding support: The Hopkins Lupus cohert is supported by NIH AR 43727 .
PY - 2014/6
Y1 - 2014/6
N2 - The prognosis and survival of patients with systemic lupus erythematosus (SLE) have improved over the past few decades. The major cause of death is no longer active lupus, but instead cardiovascular disease, complications of renal failure, and malignancy. Co-morbid factors, including both traditional and non-traditional cardiovascular risk factors, can be targeted according to accepted guidelines. We will emphasize the deleterious effect of corticosteroids in contributing to cardiovascular risk and the need to shift maintenance prednisone doses to a much lower threshold.
AB - The prognosis and survival of patients with systemic lupus erythematosus (SLE) have improved over the past few decades. The major cause of death is no longer active lupus, but instead cardiovascular disease, complications of renal failure, and malignancy. Co-morbid factors, including both traditional and non-traditional cardiovascular risk factors, can be targeted according to accepted guidelines. We will emphasize the deleterious effect of corticosteroids in contributing to cardiovascular risk and the need to shift maintenance prednisone doses to a much lower threshold.
UR - http://www.scopus.com/inward/record.url?scp=84902553318&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84902553318&partnerID=8YFLogxK
U2 - 10.1016/j.lpm.2014.03.009
DO - 10.1016/j.lpm.2014.03.009
M3 - Short survey
C2 - 24855047
AN - SCOPUS:84902553318
SN - 0755-4982
VL - 43
SP - e187-e195
JO - Nouvelle Presse Medicale
JF - Nouvelle Presse Medicale
IS - 6P2
ER -